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Monitoring temporal trends of antimicrobial resistance can
provide useful information for the empirical selection of
antimicrobial agents to treat infected patients and for the
control of nosocomial infections. In this study, we analyzed
antimicrobial resistance of clinically relevant bacteria in 2003
at Korean hospitals and at a commercial laboratory. The follo-
wing organism-antimicrobial agent resistance combinations
were very prevalent: oxacillin-resistant Staphylococcus aureus
(68%), expanded-spectrum cephalosporin-resistant Klebsiella
pneumoniae (25%), and fluoroquinolone-resistant Escherichia
coli (33%), Acinetobacter spp. (58%), and Pseudomonas aeru-
ginosa (40%). Moreover, gradual increases in vancomycin-
resistant Enterococcus faecium (20%), cefoxitin-resistant E.
coli (10%) and K. pneumoniae (23%), and imipenem-resistant
P. aeruginosa (20%) and Acinetobacter spp. (13%) were also
observed. The resistance rates of Acinetobacter spp. to most
antimicrobial agents at hospitals and at the commercial labora-
tory were similar. Among the Acinetobacter spp. isolated at
a tertiary-care hospital, 46.2% were multidrug-resistant to 9-12
of 13 antimicrobial agents, and 18.3% were panresistant. The
exclusion of duplicate isolates at a tertiary-care hospital signi-
ficantly lowered the proportion of oxacillin-resistant S. aureus,
vancomycin-resistant E. faecium, and fluoroquinolone-resis-
tant E. coli.
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INTRODUCTION
Antimicrobial agents have significantly contri-
buted to the improvement of human health and
welfare,1 but alarming rises in the prevalence of
resistance to some agents among certain groups of
bacteria have been noted. The increasing antimi-
crobial resistance of bacteria is a worldwide pro-
blem, albeit the prevalence varies greatly by
country because it is influenced by the differences
in antimicrobial usage and spread of resistance.
With the increase of resistant bacteria, useful
information for the treatment of infected patients
can be obtained only by determining the suscep-
tibility. However, isolation of etiologic agents is
not always possible. Even when possible, it takes
time to obtain the results. Therefore, initial anti-
biotic therapy is typically empirical. Empirical
selection of the most appropriate antibiotic is
possible only when the current regional resistance
pattern is known.
Necessary steps to manage antimicrobial resis-
tance problem include the use of better surveil-
lance to accurately assess the extent of problems.
Antimicrobial resistance surveillance is defined as
the systematic collection, analysis, and dissemi-
nation of data that can be used to identify resis-
tance trends and to assess the need for interven-
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tion.2 Monitoring temporal trends of resistance is
considered most beneficial for the detection of
subtle changes in resistance.3
The most accurate information can be obtained
by collecting clinical isolates from participating
hospitals and testing them in a reference labora-
tory. However, this method cannot analyze many
isolates and is costly. Examples of such studies
include the Alexander, PROTEKT, and SENTRY
program.4,5 Another commonly used resistance
surveillance method is the analysis of routine
susceptibility test data at hospitals because it does
not require extensive resources,5,6 although it has
inherent inaccuracies due to differences in metho-
dology and interpretation.
Based on a World Health Organization (WHO)
recommendation to organize a national surveill-
ance program, the KONSAR study was initiated
in 1997.7 In Korea, two surveillance methods have
been used: annual analysis of test data generated
by KONSAR-participating hospitals,8 and the
collection and testing of problematic organism-
antimicrobial combinations by the coordinating
laboratory.9,10 The latter program showed wide
dissemination of metallo- -lactamase (MBL)-proβ -
ducing Acinetobacter spp. and Pseudomonas spp.,
and plasmid-mediated AmpC enzyme-producing
Escherichia coli and Klebsiella pneumoniae.
In the present surveillance, some modifications
were made. Recently, the increase of multidrug-
resistant (MDR) Acinetobacter spp. has become a
concern in many countries because relatively few
antibacterial drugs remain active against this
microbe.
11
Therefore, in addition to analyzing
resistance rates, MDR patterns of Acinetobacter
spp. at the coordinating hospital were also an-
alyzed in this study. The higher resistance rates of
nosocomially-acquired strains compared to com-
munity-acquired strains necessitate differentiation
between the two groups. However, in a large-
scale study it is difficult to separate these groups
appropriately. In the previous KONSAR surveil-
lance, data were collected from hospitals only.
However, in this study, data were also collected
from a commercial laboratory, which examined a
large number of specimens submitted mostly from
primary-care clinics located outside of Seoul.
In the analysis of resistance data, NCCLS
12
recommends excluding duplicate isolates from a
single patient, although previous KONSAR sur-
veillances have included duplicate isolates. When
duplicate isolates are included, resistance rates
increase, particularly in drug-resistant nosocomial
pathogens such as Staphylococcus aureus and
Pseudomonas aeruginosa. However, the elimination
of duplicate isolates may mask trends in emerging
resistance.6 In this study, the effect of excluding
duplicate isolates on the resistance rates in S.
aureus, Enterococcus faecium, and E. coli was
analyzed using data from the coordinating hos-
pital.
MATERIALS AND METHODS
Routine susceptibility test data on the most
clinically relevant aerobic bacteria in 2003 were
collected from 44 hospitals located in large cities
and small provincial in Korea. The data from five
of the 44 hospitals were excluded from analysis
due to the hospitals' poor performance in the
WHO/CDC quality control program. Less than 10
isolates of non-typhoidal Salmonella and less than
20 isolates of other organisms from a hospital
were also excluded from the analysis.
Hospitals were divided into three groups
according to location and bed capacity ( 1000
beds countrywide, <1000 beds in Seoul, and <
1000 beds in non-Seoul). Resistance rates did not
include intermediate susceptibility. The mean
resistance rates in each hospital group were cal-
culated from the resistance rates at each hospital,
thus minimizing the influence of a large number
of isolates and the high prevalence of resistance
at some hospitals.5,13 Test data obtained at a
commercial laboratory were analyzed separately.
The resistance rates were calculated from all
isolates, including duplicate isolates. However,
the effect of excluding duplicate isolates was an-
alyzed using the data for S. aureus, E. faecium, and
E. coli at the coordinating hospital. MDR patterns
of Acinetobacter spp. at the coordinating hospital
were analyzed using the WHONET 5 program.14
Statistical analysis of resistance surveillance data,
which was considered difficult,2 was not per-
formed in this surveillance, as has been the com-
mon practice in large scale and continuous sur-
veillance programs.4,15
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RESULTS
Rank order of isolates and method appropri-
ateness
The number of isolates in 2003 slightly in-
creased compared to the number in 2002, but the
rank order remained identical for 11 of 13
organisms with a large number of isolates (Table
1). The most prevalent species in hospitals was S.
aureus (20.0%), while in the commercial labora-
tory it was E. coli (27.8%). The proportions of E.
faecium to E. faecalis differed considerably in hos-
pitals compared to the commercial laboratory, at
81.9% vs. 15.8%, respectively.
To test E. coli, the NCCLS disk diffusion method,
broth microdilution method (Vitek [bioMerieux,
Marcy l'Etoile, France] or MicroScan [Dade
MicroScan Inc., West Sacramento, CA, U.S.A.]
system), or a combination of the two methods
were used by 11, 27, and three laboratories, re-
spectively. Oxacillin disks were used to differen-
tiate oxacillin (methicillin)-resistant staphylococci
and to screen penicillin G-non-susceptible pneu-
mococci. To test fluoroquinolone susceptibility of
gram-negative bacilli, the majority of hospitals
used ciprofloxacin, while others used levofloxacin.
The antimicrobial agents used in 2003 to test the
susceptibility of E. coli and S. aureus were similar
to those used in 2002 (Table 2). Less than 70% of
the hospitals tested the susceptibility of E. coli to
cephalothin, piperacillin, and cotrimoxazole, and
only 50% of the hospitals tested the susceptibility
of S. aureus to cotrimoxazole. Method analysis of
38 laboratories showed that the types of anti-
microbial agents tested were 8-10, 15-20, and 16-
21, at 5, 20, and 13 laboratories, respectively (data
not shown).
Resistance at hospitals and at a commercial
laboratory
The mean resistance rates (Table 3) of S. aureus
were much higher than those of coagulase-nega-
tive staphylococci (CNS) to clindamycin (59% vs.
36%) and to ciprofloxacin (61% vs. 38%), but
slightly lower to oxacillin (68% vs. 73%) and to
cotrimoxazole (16% vs. 39%). Seventy percent of
Streptococcus pneumoniae were resistant to oxa-
cillin, suggesting penicillin non-susceptibility. The
ampicillin and vancomycin resistance rates of E.
faecium were 88% and 20%, respectively.
Table 1. Comparison of the Number, Proportion, and Rank of Isolates in 2002 and 2003
Organism
2002 2003
Hospitals Hospitals Commercial Lab.*
No. (%) of isolates Rank No. (%) of isolates Rank No. (%) of isolates Rank
Escherichia coli 36,197 (17.5) 2 40,651 (18.9) 2 7,825 (27.8) 1
Klebsiella pneumoniae 17,956 (8.7) 5 18,635 (8.6) 5 2,535 (9.0) 5
Enterobacter cloacae 7,509 (3.6) 9 7,505 (3.5) 9 794 (2.8) 9
Serratia marcescens 5,643 (2.7) 10 5,474 (2.5) 10 1,306 (4.6) 8
Nontyphoidal Salmonella 1,170 (0.6) 12 759 (0.4) 13 232 (0.8) 12
Acinetobacter spp. 17,330 (8.4) 6 15,957 (7.4) 6 1,342 (4.9) 7
Pseudomonas aeruginosa 30,342 (14.7) 3 28,163 (13.1) 3 4,064 (14.4) 2
Haemophilus influenzae 938 (0.5) 13 1,248 (0.6) 12 165 (0.6) 13
Staphylococcus aureus 42,798 (20.7) 1 43,003 (20.0) 1 3,776 (13.4) 3
Coagu lase-nega tiv e staphy lococc i 21,884 (10.6) 4 24,567 (11.3) 4 3,044 (10.8) 4
Enterococcus faecalis 11,806 (5.7) 7 13,685 (6.3) 7 2,352 (8.4) 6
E. faecium 9,051 (4.4) 8 11,202 (5.2) 8 371 (1.3) 10
Streptococcus pneumoniae 3,944 (1.9) 11 4,652 (2.2) 11 336 (1.2) 11
Total 206,568 (100) 215,501 (100) 28,343 (100)
*The majority of the specimens were collected from primary care clinics outside of Seoul.
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The cefotaxime and fluoroquinolone resistance
rates of E. coli were 11% and 33%, respectively,
and those of K. pneumoniae to ceftazidime and
cefoxitin were 25% and 23%, respectively (Table
4). The lowest resistance rates shown by Entero-
bacter cloacae and S. marcescens to cephalosporins
were to cefepime and were 8% and 19%, respec-
tively. Imipenem-resistant K. pneumoniae, E.
cloacae, and Serratia marcescens isolates existed,
although their rates were very low.
Lower resistance rates were shown by P.
aeruginosa to ceftazidime (19%) and imipenem
(20%) and by Acinetobacter spp. to imipenem (13%)
and cefoperazone-sulbactam (15%). The resistance
rates of non-typhoidal Salmonella to ampicillin,
cotrimoxazole, and fluoroquinolone were 29%,
4%, and 0.3%, respectively (data not shown). The
ampicillin resistance rate of Haemophilus influenzae
was 54%, and a test of part of the isolates showed
that 52% produced -lactamase (data not shown).β
The resistance rates of staphylococci to all anti-
microbial agents, except for cotrimoxazole resis-
tance of S. aureus (Table 3), were much lower at
the commercial laboratory than at the hospitals.
The ampicillin resistance rates of E. faecium were
equal at the hospitals and the commercial labo-
ratory (88%), but the vancomycin resistance rates
were 20% at the hospitals and 7% at the com-
mercial laboratory. Compared to the resistance
rates at the hospitals, the rates at the commercial
laboratory were: similar in cefotaxime and fluoro-
quinolone resistance of E. coli (12% and 31%, re-
spectively); slightly lower in cefoxitin resistance of
K. pneumoniae (18%); much lower in cefotaxime,
ticarcillin-clavulanic acid, amikacin, and fluoro-
quinolone resistance of E. cloacae and S. marces-
cens; slightly lower in ceftazidime and imipenem
resistance of P. aeruginosa (15% and 17%, respec-
tively); and much lower in ampicillin-sulbactam
and imipenem resistance of Acinetobacter spp.
(22% and 5%, respectively) (Table 4).
Trends of significant resistance
The trends of significant resistance in staphylo-
cocci, enterococci, K. pneumoniae, and Acinetobacter
spp. are shown in Fig. 1-3. As in 2002, the oxacil-
lin resistance rate was slightly higher in CNS than
in S. aureus in 2003 (Fig. 1). Not only did the
ampicillin resistance of E. faecium remain highly
prevalent, but vancomycin resistance reached 20%
in 2003. The ceftazidime and cefoxitin resistance
rates of K. pneumoniae in 2003 were higher than
those in 2002, and a gradual increase in the
Table 2. Proportion of Hospitals Which Used Antimicrobial Agents for the Susceptibility Testing of E. coli and S. aureus
in 2002 and 2003*
Species
CLSI group and
antimicrobial agents
% of hospitals
Species
CLSI group and
antimicrobial agents
% of hospitals
2002 2003 2002 2003
E. coli Group A E. coli Group B (Control)
Ampicillin 95 95 Cotrimoxazole 54 43
Cephalothin 67 61 Fluoroquinolone 100 100
Gentamicin 97 100
Group B S. aureus Group A
Ampicillin-sulbactam 82 80 Penicillin G 95 89
CTX, CAZ, ATM 95 95 Oxacillin 100 100
Cefepime 67 73 Group B
Cefoxitin 64 70 Clindamycin 97 93
Piperacillin 39 36 Erythromycin 97 95
Piperacillin-tazobactam 74 77 Cotrimoxazole 59 50
Imipenem 92 98 Vancomycin 97 95
Amikacin 97 98
*The number of participating laboratories was 39 in 2002 and 44 in 2003.
CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; CLSI, clinical laboratory standards institute.
Table 4. Antimicrobial Resistance Rates of Enterobacteriaceae, P. aeruginosa, and Acinetobacter spp. Tested at Hospitals
and at a Commercial Laboratory
Antimicrobial
agents
Percent of isolates resistant (No. of isolates tested)
E. coli K. pneumoniae E. cloacae S. marcescens P. aeruginosa Acinetobacter spp.
Hosp ita ls
(40,651)
C lin ics
(7,900 )
Hosp ita ls
(18,635 )
C lin ics
(2 ,500 )
Hosp ita ls
(7 ,508 )
C lin ics
(790)
Hosp ita ls
(5 ,474 )
C lin ics
(1 ,300 )
Hosp ita ls
(28,163 )
C lin ics
(4 ,100)
Hosp ita ls
(15 ,957 )
C lin ics
(1 ,400)
Ampicillin 71 NT - - - - - - - - - -
Ampicillin-Sulb 33 26 34 30 - - - - - - 47 22
Cephalothin 39 33 36 36 - - - - - - - -
Cefotaxime 11 12 20 18 36 15 31 16 61 NT 67 64
Ceftazidime 10 NT 25 NT 38 NT 23 NT 19 15 55 NT
Aztreonam 9 NT 24 NT 34 NT 25 NT 26 16 73 NT
Cefepime 8 NT 14 NT 8 NT 19 NT 21 NT 41 NT
CFP-Sulb 5 NT 10 NT 16 NT 37 NT 20 NT 15 NT
Cefoxitin 10 6 23 18 - - - - - - - -
Cefotetan 4 NT 12 NT - - - - - - - -
Piperacillin 52 NT 39 NT 46 NT 40 NT 38 39 60 NT
Piperacillin-Tazo 5 NT 14 NT 23 NT 25 NT 25 NT 42 NT
Ticarcillin-Clv 15 5 25 14 48 22 42 28 45 44 37 34
Imipenem 0.1 0 0.3 0 0.2 0 1.2 0 20 17 13 5
Meropenem 0.1 NT 0.5 NT 0.1 NT 0.8 NT 20 NT 25 NT
Amikacin 5 5 13 19 10 6 24 10 25 28 54 55
Gentamicin 28 25 21 27 26 25 42 19 42 45 64 64
Tobramycin 21 NT 32 NT 36 NT 47 NT 39 41 65 NT
Fluoroquinolone 33 31 19 19 12 6 22 9 40 46 58 65
Cotrimoxazole 53 44 31 30 31 29 25 38 94 NT 57 56
Tetracycline 56 NT 23 NT 31 NT 72 NT 95 NT 51 NT
*-, not applicable because of natural resistance.
NT, not tested; CFP, cefoperazone; Sulb, sulbactam; Tazo, tazobactam; Clv, clavulanic acid.
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Table 3. Antimicrobial Resistance Rates of Staphylococci, Pneumococci, and Enterococci Tested at Hospitals and at a
Commercial Laboratory
Antimicrobial agents
Percent of isolates resistant (No. of isolates tested)
S. aureus CNS S. pneumoniae E. faecalis E. faecium
Hospitals
(43,003)
C-Lab
(3,800)
Hospitals
(24,567)
C-Lab
(3,100)
Hospitals
(4,652)
C-Lab
(336)
Hospitals
(13,685)
C-Lab
(2,350)
Hospitals
(11,202)
C-Lab
(370)
Oxacillin 68 55 73 69 70* NT NT NT NT NT
Penicillin/ampicillin 97 95 93 92 NT NT 0.6 1 88 88
Clindamycin 59 42 36 19 NT NT NT NT NT NT
Erythromycin 69 60 58 45 72 77 NT NT NT NT
Cotrimoxazole 16 21 39 32 NT NT NT NT NT NT
Tetracycline 56 50 40 45 NT NT 81 84 17 15
Gentamicin 66 58 56 46 NT NT NT NT NT NT
Ciprofloxacin 61 48 38 25 NT NT 35 28 88 81
Teicoplanin 0.03 NT 0.2 NT NT NT 0.8 0 17 2
Vancomycin 0 0 0.03 0 NT NT 0.9 0 20 7
*Indicates proportion of penicillin-nonsusceptible isolates.
Penicillin for staphylococci and ampicillin for enterococci.
C-Lab, commercial laboratory; CNS, coagulase-negative staphylococci; NT, not tested.
Kyungwon Lee, et al.
Yonsei Med J Vol. 47, No. 1, 2006
fluoroquinolone and amikacin resistance rates is
apparent in the last several years (Fig. 2). A slight
decline of Acinetobacter spp. resistance to amikacin,
fluoroquinolone, and ceftazidime was noted, but
the rates remained over 50% (Fig. 3). Imipenem-
resistant Acinetobacter spp. gradually increased,
reaching 13% in 2003.
Comparing the resistance rates between hospital
groups, vancomycin-resistant E. faecium, fluoro-
quinolone-resistant E. coli, and cefoxitin-resistant
K. pneumoniae were more prevalent at larger
hospitals. Large differences in resistance rates
were observed between the large hospital group
and the commercial laboratory for vancomycin-
resistant E. faecium (25% and 7%, respectively),
and for imipenem-resistant Acinetobacter spp. (11%
and 5%, respectively) (Fig. 4).
MDR Acinetobacter spp.
MDR patterns of Acinetobacter spp. to 13 antimi-
crobial agents were determined excluding dupli-
cate isolates and isolates with less than a 1%
pattern (Fig. 5). Among the 925 isolates analyzed,
11.5% were resistant to none of the antimicrobial
agents (data not shown), but 18.3% were resistant
to all of the drugs, and 11.5%, 11.6% and 18.6%
showed MDR to 10, 11, and 12 antimicrobial
agents, respectively.
Resistance rates excluding duplicate isolates
Resistance rates were lowered by more than
20% after the exclusion of duplicate isolates from
the coordinating laboratory data of the following:
clindamycin and cotrimoxazole resistance of S.
aureus, teicoplanin and vancomycin resistance of
E. faecium, and ampicillin-sulbactam, ticarcillin-
clavulanate, piperacillin-tazobactam, cefotaxime,
ceftazidime, aztreonam, cefoperazone-sulbactam,
Fig. 1. The resistance trends of staphylococci to oxacillin,
and E. faecium to ampicillin and vancomycin. Continued
high prevalence of oxacillin-resistant staphylococci, ampi-
cillin-resistant E. faecium, and a gradual increase of van-
comycin-resistant E. faecium were observed. OXA, oxacil-
lin; AMP, ampicillin; VAN, vancomycin; R, resistant;
SAU, S. aureus; CNS, coagulase-negative staphylococci;
EFM, E. faecium.
Fig. 2. The resistance trend of K. pneumoniae to cefoxitin,
ceftazidime, amikacin, and fluoroquinolone. The cefta-
zidime resistance rate remained high, while a tendency
of increasing resistance to other antimicrobial agents was
observed. FOX, cefoxitin; CAZ, ceftazidime; AMK, ami-
kacin; FQN, fluoroquinolone.
Fig. 3. The resistance trend of Acinetobacter spp. to ami-
kacin, fluoroquinolone, and ceftazidime remained high,
and a tendency for increasing imipenem-resistance was
observed. AMK, amikacin; FQN, fluoroquinolone; CAZ,
ceftazidime; IMP, imipenem.
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cefoxitin, cefotetan, amikacin tobramycin, and
ciprofloxacin resistance of E. coli (Table 5).
Table 5. Comparison of Resistance Rates Calculated from All Isolates and from the First Isolates per Patient per Year
at a Tertiary-care Hospital*
Species Antimicrobial agent
Resistant isolates (%)
Species Antimicrobial agent
Resistant isolates (%)
All 1st All 1st
S. aureus n = 3,723 n = 1,793 E. coli Piperacillin 62 57
Oxacillin 71 58 (Control) Ampicillin-sulbactam 31 24
Penicillin 95 94 Ticarcillin-clavulanate 11 8
Clindamycin 60 48 Piperacillin-tazobactam 6 4
Erythromycin 71 61 Cephalothin 40 34
Cotrimoxazole 18 12 Cefotaxime 11 7
Tetracycline 52 46 Ceftazidime 8 5
Ciprofloxacin 66 53 Aztreonam 8 5
Cefepime 3 3
E. faecium n = 1,864 n = 1,032 Cefoperazone-sulbactam 3 2
Ampicillin 97 95 Cefoxitin 10 6
Tetracycline 9 11 Cefotetan 5 3
Ciprofloxacin 95 93 Amikacin 9 5
Teicoplanin 22 15 Gentamicin 31 25
Vancomycin 29 21 Tobramycin 27 20
Cotrimoxazole 46 41
E. coli n = 3,138 n = 2,206 Tetracycline 58 56
Ampicillin 74 69 Fluoroquinolone 33 25
*Vancomycin- and teicoplanin-resistant S. aureus and imipenem- and meropenem-resistant E. coli isolates were absent.
Fig. 4. Antimicrobial resistances of strains isolated at
three hospital groups and tested at a commercial labora-
tory. Resistance rates were generally higher in the large
hospital group. Vancomycin-resistant E. faecium and im-
ipenem-resistant Acinetobacter spp. were much less pre-
valent among the commercial laboratory tested strains.
S-med, Seoul-medium; N-med, non-Seoul-medium; Comm
Lab, commercial laboratory; VAN, vancomycin; FQN,
fluoroquinolone; FOX, cefoxitin; IPM, imipenem; EFM, E.
faecium; ECO, E. coli; KPN, K. pneumoniae; PAE, P.
aeruginosa; ABA, A. baumannii.
Fig. 5. Multi-resistance of Acinetobacter spp. isolated at a
tertiary-care hospital. Among the isolates 11.5% were
resistant to none of the 13 antimicrobial agents tested,
but 18.3% were resistant to all of the agents tested.
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DISCUSSION
It is stressed that surveillance is an important
part of modern clinical microbiology, because
only resistance surveillance can provide the neces-
sary information for empirical selection. For ex-
ample, it has been suggested that when resistance
to a particular drug occurs in >10-20% of isolates,
the drug should not be used for empirical
treatment.6 Isolation rank based on the first isolate
in a patient has been recommended by NCCLS12
for reporting laboratory surveillance data, with
the primary aim of guiding clinicians in the selec-
tion of empirical therapy. However, when only
the first isolates are included, resistance selection
occurring within the observation period cannot be
detected.6 In our present study, duplicate isolates
were included, as in the previous surveillances,
because we considered the information gained by
including duplicate isolates to be useful for the
control of nosocomial infections.
The proportions of each species were very simi-
lar in 2002 and 2003: S. aureus, E. coli, P. aeruginosa,
CNS, and K. pneumoniae remained in the same
rank order of 1 to 5, respectively. However, at the
commercial laboratory, E. coli, P. aeruginosa, and S.
aureus were ranked 1 to 3, respectively. It is dif-
ficult to compare the rank orders without knowl-
edge of the specimens, but it can be assumed that
the difference was probably due to a relatively
low prevalence of nosocomial pathogens at clinics
(Table 1).
With the increase in MDR bacteria, limiting sus-
ceptibility testing only to a few classes of anti-
microbial agents cannot provide sufficient infor-
mation for patient treatment. However, as in 2002,
some laboratories tested susceptibility to only a
small number of antimicrobial agents (Table 2).
For optimal detection of extended-spectrum -β
lactamase (ESBL)-producing E. coli and K. pneumo-
niae, the use of both ceftazidime and cefotaxime
is recommended.16 Due to the increasing preva-
lence of CTX-M type ESBLs, the concomitant
testing of cefotaxime susceptibility is now impor-
tant in Korea,
17
as in other countries.
18
However,
some laboratories tested susceptibility to only one
expanded-spectrum cephalosporin, as was the
case in 2002. A previous study with collected
strains showed a high prevalence of plasmid-
mediated AmpC enzyme DHA-1-producing K.
pneumoniae,10 indicating the need for susceptibility
testing to cefoxitin and cefepime. However, many
laboratories did not test for these drugs in 2002
or 2003.
The present surveillance showed that the oxacil-
lin-resistant S. aureus (ORSA) and oxacillin-re-
sistant CNS remained very high, at approximately
70% (Fig. 1). This trend is similar to that in
Japan.19 ORSA is now a worldwide problem: the
proportions were more than 40% in Greece, Italy,
and the United Kingdom in 1999-2002.20 In the
present surveillance, penicillin-non-susceptible
pneumococci (based on the breakpoint for the
treatment of meningitis) also remained very pre-
valent as was observed in other Asian countries.21
Increases in penicillin resistance were also re-
ported in the United States in the 1990s.22
The gradual increase of vancomycin-resistant E.
faecium continued and reached 20% in the hos-
pital groups in 2003 (Fig. 2). The rate was much
higher in the large hospital group (25%) than in
the smaller non-Seoul hospital group (14%), and
was only 7% in the commercial laboratory (Table
4), suggesting the influence of nosocomial disse-
mination. The higher rate observed at a tertiary-
care hospital was partly due to the inclusion of
duplicate isolates (Table 5). Difficulties in the
control of vancomycin-resistant enterococci were
shown by their high prevalence in a U.S. hos-
pital.23 E. faecium increased from 12.7% to 22.2%
from 1993 to 2002 among all enterococcal isolates,
which included one isolate per patient per month,
and vancomycin-resistant isolates increased from
28.9% to 72.4%, respectively.
The high prevalence of ampicillin-resistant E.
coli (71%) in our study was similar to the rate in
Taiwan (78%).24 The ampicillin resistance rate of
H. influenzae (53%) was similar to the -lactamaseβ
positive rate of 52% (data not shown). This result
suggests that -lactamase-negative ampicillin-β
resistant (BNAR) H. influenzae remains rare in
Korea, although it is a prevalent type in Japan.25
The increase in isolates of ampicillin-resistant
non-typhoidal Salmonella may indicate an in-
creasing prevalence of this resistance in the com-
munity, as the infections are more often com-
munity-acquired rather than nosocomially-ac-
quired. However, the resistance rates were much
Korean Surveillance of Antimicrobial Resistance in 2003
Yonsei Med J Vol. 47, No. 1, 2006
lower than those of Salmonella enterica serovar
Typhymurium DT104 isolates, which were 34%
for both ampicillin and cotrimoxazole.26 The cipro-
floxacin resistance rate was only 0.3%, but this
rate probably cannot be used to predict clinical
efficacy in the treatment of extraintestinal infec-
tions because low-level quinolone resistance can-
not be detected by using fluoroquinolones.16
E. coli and K. pneumoniae often acquire ESBL
genes. In this study, 11% of E. coli and 25% of K.
pneumoniae were resistant to cefotaxime and
ceftazidime, respectively, suggesting ESBL pro-
duction. In Korea, TEM-, SHV-, and CTX-M-type
ESBLs were previously reported.17,27 Cefoxitin-
resistant E. coli (10%) and K. pneumoniae (23%)
may be partly due to plasmid-mediated AmpC
enzymes, such as DHA-1 and CMY-1-like, which
are prevalent in Korea.10 Carbapenems are the
only class of -lactam agents active against strainsβ
producing ESBLs and hyperproducing AmpC
enzymes.28 Therefore, the increasing carbapenem
resistance in P. aeruginosa and Acinetobacter spp. is
the most serious problem. The imipenem resis-
tance rate of Acinetobacter spp. (13%) was lower
than that of P. aeruginosa (20%), but interestingly,
the rate of the former has increased rapidly since
2002 (Fig. 3), while that of the latter remained
similar (data not shown). Among the isolates in
2000 and 2001, VIM-2 and IMP-1 MBL genes were
detected in Acinetobacter isolates, but only the
VIM-2 gene was detected in P. aeruginosa isolates.9
Kim et al.29 tested 116 imipenem-resistant P.
aeruginosa isolates from 2000 to 2003 at a tertiary-
care hospital, and detected 19 (16.4%) VIM-2 gene-
positive isolates. These data indicate a wide dis-
semination of MBL-producing P. aeruginosa and
Acinetobacter spp. A study with 3,233 strains of P.
aeruginosa isolated at 37 medical institutes in
Japan showed an imipenem resistance rate of
19.0%, which was similar to our results, but the
rates to all other antimicrobial agents were lower
than our results.30 Jeong et al.31 reported a
VIM-2-producing E. cloacae isolate in 2003. In the
present study, imipenem-resistant isolates were
also present in K. pneumoniae, although the
proportion was very low.
The resistance of E. coli and K. pneumoniae to
gentamicin and tobramycin in this study were not
very high (21% and 32%, respectively). Previously,
amikacin-resistant gram-negative bacilli were very
rare. However, the resistance rates of gram-nega-
tive bacilli other than E. coli were high at 10% to
54% (Table 4), making empirical use of the drug
difficult. Fluoroquinolones are frequently used, as
they are one of the three major broad-spectrum
classes of antimicrobial agents.32 The fluoroqui-
nolone resistance rate of E. coli in 2003 (33%) was
similar to that in 2002. We found similar fluoro-
quinolone resistance rates of E. coli, P. aeruginosa
and Acinetobacter spp. at the commercial labora-
tory and at the hospitals (Table 4), which also
suggests the prevalence of this resistance in the
community.
It is concerning that Acinetobacter spp. isolates
are often MDR. Abbo et al.33 reported that they
were unable to clearly define the mode of
spreading and the reason for the emergence of
MDR A. baumannii. Analysis of Acinetobacter spp.
isolated at the coordinating laboratory showed
that 46.2% of the isolates were MDR to 9 to 12 of
the 13 antimicrobial agents tested, and 18.3% were
panresistant (Fig. 5). MDR and panresistant
Acinetobacter has been reported in other countries
as well.33,34 In Brazilian hospitals, resistance rates
of Acinetobacter spp. to carbapenem have reached
12% or higher.35 Thus, more toxic agents, such as
polymyxin, have been used. Consequently, it was
found that 5 of 100 Acinetobacter blood isolates
were resistant to this drug.
Ideally, multi-center surveillance should be
representative of all types and sizes of institutions;
however, current surveillance tends to include
only larger university-affiliated hospitals, which
may overrepresent the prevalence of resistance
due to the types of patients treated at large
hospitals.36 Accurate resistance surveillance of a
community-acquired pathogen was considered to
be difficult because of sampling bias. For example,
physicians' requests for urine culture have de-
creased recently, and cultures have been per-
formed relatively more often for patients with
failed antimicrobial therapy.36 In the analysis of
surveillance data, making the distinction between
nosocomial and community-acquired infections is
also difficult.15 In the present study, as in previous
studies, we did not separate community-acquired
from nosocomially-acquired strains due to the
difficulty of separation. Instead, the resistances of
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strains at a commercial laboratory, which were
mostly from primary-care clinic patients, were
compared to those at hospitals. Our results
showed that resistance rates at the commercial
laboratory were generally lower, but it was dif-
ficult to generalize the resistance patterns.
It is well known that excluding duplicate iso-
lates lowers resistance rates. Lee et al.37 reported
an overestimation of MRSA when duplicate iso-
lates were included. In our analysis of data from
a tertiary-care hospital, including only the first
isolate/patient/year reduced proportions of ORSA
by 18%, vancomycin-resistant E. faecium by 28%,
and fluoroquinolone-resistant E. coli by 24%
(Table 5). However, the effect was minimal in the
resistance rates to old antimicrobial agents, i.e.,
penicillin-resistant S. aureus, ampicillin-resistant E.
faecium, and ampicillin- and fluoroquinolone-
resistant E. coli. When duplicate isolates are ex-
cluded from analysis, the emergence of resistance
that occurs within the observation period may not
be seen, thereby giving an overly optimistic view
of the percentage of susceptible strains.3,6 Also,
there could be a question as to the removal
period, i.e., 5 days, 30 days, or 365 days.
In conclusion, oxacillin-resistant staphylococci,
expanded-spectrum cephalosporin-resistant K.
pneumoniae, and fluoroquinolone-resistant E. coli,
Acinetobacter spp., and P. aeruginosa remain very
prevalent in Korea. Vancomycin-resistant E. faecium,
cefoxitin-resistant E. coli and K. pneumoniae, and
imipenem-resistant P. aeruginosa and Acinetobacter
spp. have gradually increased. The resistance rates
of Acinetobacter spp. to most antimicrobial agents
tested at hospitals and at a commercial laboratory
were similar, suggesting dissemination of this
problematic organism in Korea. Analysis of the
data from a tertiary-care hospital showed the
prevalence of MDR and panresistant Acinetobacter
spp. The exclusion of duplicate isolates lowered
the proportion of ORSA, vancomycin-resistant E.
faecium, and fluoroquinolone-resistant E. coli sig-
nificantly. In future surveillances, more useful
information could be obtained by determining the
resistance trends of problematic antibiotic-bacteria
combinations at both hospitals and commercial
laboratories. Also, more information could be
gained by presenting resistance data that both
includes and excludes duplicate isolates.
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